Cosmos Health Inc. Stock Price, News & Analysis

Cosmos Health (NASDAQ:COSM) has received an additional 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement. The company now has until November 3, 2025, to meet the $1.00 minimum bid price threshold. This extension follows the initial 180-day compliance period that expired on May 5, 2025, after COSM was first notified of non-compliance on November 6, 2024.

The second compliance period was granted as Cosmos Health meets all other Nasdaq Capital Market listing requirements. To regain compliance, the company's stock must maintain a closing bid price of at least $1.00 for a minimum of 10 consecutive business days during this period.

CEO Greg Siokas expressed confidence in meeting the listing requirements within the extended timeframe while focusing on executing strategic priorities.

Cosmos Health CEO Greg Siokas has significantly increased his stake in the company by purchasing 1,466,764 common shares valued at $526,000 through five transactions between April 21-24, 2025. This recent investment brings his total beneficial ownership to 5,582,066 shares.

Over the past five months, Siokas has invested more than $1.3 million, adding over 2.7 million shares to his holdings. His total investment in the company since inception now exceeds $18 million.

As a vertically integrated global healthcare group, Cosmos Health focuses on:

• Innovative R&D
• Proprietary pharmaceutical and nutraceutical brands
• Healthcare product manufacturing and distribution
• Telehealth platform operations

The CEO expressed confidence in the company's direction and commitment to creating shareholder value.

Cosmos Health (NASDAQ:COSM) reported its full-year 2024 financial results, showing a 2% revenue increase to $54.43 million from $53.38 million in 2023. The company achieved a significant 24.16% reduction in operating expenses to $19.86 million, including a 40.26% cut in administrative expenses and 71% decrease in marketing costs.

Gross margin slightly declined to 7.92% from 8.15% in 2023. The company reported an Adjusted EBITDA of negative $3.73 million, compared to positive $0.06 million in 2023. Total assets decreased by 17.72% to $54.31 million, while maintaining a 55% liabilities-to-assets ratio.

Key developments include AI-driven patent filings for multiple diseases, advancement of weight management solution CCX0722, expansion of manufacturing capabilities, and securing a €2.2 million bond loan at 2.95% interest plus Euribor. The company also expanded its Sky Premium Life brand globally and integrated cryptocurrency as treasury reserve assets.

Cosmos Health (NASDAQ:COSM) announces completion of manufacturing upgrades at its subsidiary Cana Laboratories and signs a significant 5-year contract manufacturing agreement with Pharmex S.A. The deal involves producing 300,000 bottles annually of the antiseptic drug AMBITASOL 1L, totaling 1.5 million units over the contract period.

Cana Laboratories, acquired by Cosmos Health in July 2023, operates an Athens facility licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA). The facility can manufacture various pharmaceuticals including tablets, capsules, syrups, nasal sprays, creams, gels, antiseptics, and biocides.

This agreement with Pharmex, a specialty pharmaceutical company established in 1981, represents part of Cosmos Health's strategy to expand its high-margin contract manufacturing business.

Cosmos Health (NASDAQ:COSM) has announced the launch of its Sky Premium Life food supplements brand in Albania through a partnership with Pharma Cell. The company has secured an initial annual order worth $300,000 from Pharma Cell, which will serve as the distributor in Albania.

Pharma Cell, based in Tirana, is a pharmaceutical company specializing in import and export of food supplements. Founded in 2021 by CEO Elvis Punmira, the company has established a growing network of pharmacies and healthcare professionals across Albania.

Cosmos Health (NASDAQ:COSM) has announced a significant expansion of its Sky Premium Life nutraceutical brand with the addition of 60 new SKUs, bringing the total product count to over 150. The expansion supports the brand's global growth through new distribution agreements across multiple territories, including presence in pharmacies and international retail chains like Holland & Barrett, as well as e-commerce platforms like Amazon.

The company's R&D department has developed several new products, including:

• Kakadu Plum with high vitamin C concentration
• Good Morning & Good Night energy and sleep formulations
• ZenBlend for relaxation and sleep
• Skinovate for skin rejuvenation
• Electrolytes in cherry and lemon flavors

Cosmos Health (NASDAQ:COSM) has announced it will not proceed with its planned offering under Form S-1 until after filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2024. The company, which operates as a diversified healthcare group focusing on pharmaceutical and nutraceutical brands, manufacturing, distribution, and telehealth services, has postponed any potential offering until after the annual financial reporting is complete.

Cosmos Health (NASDAQ:COSM) announced entering the final development phase of CCX0722, its weight management solution. The company is finalizing scale-up production and engaging with Contract Research Organizations (CROs) to complete the technical dossier. Clinical trials are expected to complete between late 2025 and early 2026, with product launch targeted for Q1 or Q2 2026.

The product is seeking potential classification as a Class III medical device. The company aims to enter the global weight management market, valued at $142.58 billion in 2022 with an expected CAGR of 9.7% from 2023 to 2030. CCX0722 is described as a biocompatible hydrogel solution targeting the growing obesity epidemic.

Cosmos Health (NASDAQ:COSM) has filed two new patent applications for innovative cancer treatments using AI-driven drug repurposing. The first patent (N2039647) targets glioma, an aggressive brain cancer, while the second (N2039645) focuses on hematologic malignancies, including multiple myeloma.

The developments stem from the company's collaboration with Cloudpharm and the National Hellenic Research Foundation, utilizing their AI-powered Cloudscreen platform. Recent in vitro studies have validated the therapeutic potential of a repurposed marketed drug for both indications.

The global market outlook is promising, with the glioma treatment market valued at $3.58 billion in 2024, projected to reach $5.1 billion by 2032 (5.20% CAGR). The hematologic malignancies treatment market was valued at $22.23 billion in 2022, expected to reach $41.7 billion by 2032 (6.5% CAGR).